Abstract
Between 1998 and 2001, the Peruvian Ministry of Health made sweeping changes in its malaria treatment policies in response to a resurgence of disease and the spread and intensification of antimalarial drug resistance. On the Pacific Coast, the first-line treatment for uncomplicated Plasmodium falciparum malaria was changed to combination therapy with sulfadoxinepyrimethamine plus artesunate; in the Amazon region, mefloquine-artesunate combination therapy was introduced. With these changes in treatment policy, Peru became the first country in the Americas to use combination therapy with an artemisinin drug as its first-line treatment for falciparum malaria and the first country in the world to use two different drug combination therapy regimens based on an artemisinin drug in different regions of the country. This paper describes the process involved in assessing the geographic distribution and intensity of antimalarial drug resistance throughout the country and the use of that information to guide decisions related to national malaria treatment policy.
Similar content being viewed by others
Additional information
Good information about drug resistance in malaria parasites made it possible to improve programs more effectively. Peru, dominated by public programs, has shown how.
Rights and permissions
About this article
Cite this article
Ruebush, T., Neyra, D. & Cabezas, C. Modifying National Malaria Treatment Policies in Peru. J Public Health Pol 25, 328–345 (2004). https://doi.org/10.1057/palgrave.jphp.3190032
Published:
Issue Date:
DOI: https://doi.org/10.1057/palgrave.jphp.3190032